Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748784 · ClinicalTrials.gov registry record · Phase 1
ADVM-022 Intravitreal Gene Therapy for Wet AMD
A Phase 1 study, sponsored by Adverum Biotechnologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03748784 is a Phase 1 study that has completed, run by Adverum Biotechnologies. The registered enrollment target is 30 participants.
The verdict
NCT03748784, a Phase 1 study, has completed, sponsored by Adverum Biotechnologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.
Interventions
- BIOLOGICAL ADVM-022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748784
The ClinicalTrials.gov registry entry for NCT03748784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADVM-022 is the first listed.
NCT03748784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748784 about?
NCT03748784 is a clinical study titled "ADVM-022 Intravitreal Gene Therapy for Wet AMD". ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intra...
What is the current status of trial NCT03748784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-11-14. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT03748784?
The interventions under investigation include: ADVM-022 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03748784?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.